PCM
HRMY icon

Prelude Capital Management’s Harmony Biosciences HRMY Stock Holding History

Prelude Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Sell
7,860
-4,200
-35% -$132K 0.02% 799
2026
Q1 		$338K Buy
12,060
+3,900
+48% +$128K 0.03% 660
2025
Q4 		$305K Sell
8,160
-3,826
-32% -$126K 0.02% 787
2025
Q3 		$330K Buy
+11,986
New +$413K 0.03% 686
2025
Q2 		– Sell
-6,920
Closed -$230K – 1145
2025
Q1 		$230K Buy
+6,920
New +$248K 0.02% 849

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's HRMY Position: Q2 2026 in Review

Prelude Capital Management reduced its Harmony Biosciences (HRMY) stake by 35% in Q2 2026, selling an estimated $132K and leaving 7,860 shares worth $286K. The position accounts for 0.02% of the portfolio, ranked #799.

Prelude Capital Management first reported a position in HRMY in Q1 2025 and has held it in 5 quarters since. The position peaked at $338K in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Prelude Capital Management held 7,860 shares of Harmony Biosciences worth $286K as of Q2 2026.
  • Prelude Capital Management sold 4,200 Harmony Biosciences shares in Q2 2026, an estimated $132K.
  • Harmony Biosciences made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #799 holding.
  • Prelude Capital Management first reported a position in Harmony Biosciences in Q1 2025 and has held it in 5 quarters since.
  • Prelude Capital Management's Harmony Biosciences position peaked at $338K in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.